Petrus Trust Company’s Nektar Therapeutics NKTR Stock Holding History

Petrus Trust Company’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-735	Closed	-$183K	–	181
2020 Q3	$183K	Buy	+735	New	+$231K	0.02%	215

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Petrus Trust Company's NKTR Position: Q4 2020 in Review

Petrus Trust Company sold out of Nektar Therapeutics (NKTR) in Q4 2020, closing a stake of 735 shares — an estimated $183K sold.

Petrus Trust Company first reported a position in NKTR in Q3 2020 and held it in 1 quarter. The position peaked at $183K in Q3 2020. 246 funds tracked by Wall St. Rank hold NKTR as of Q4 2020.

Petrus Trust Company reported no remaining Nektar Therapeutics position as of Q4 2020 after selling out during the quarter.
Petrus Trust Company sold 735 Nektar Therapeutics shares in Q4 2020, an estimated $183K.
Petrus Trust Company first reported a position in Nektar Therapeutics in Q3 2020 and held it in 1 quarter.
Petrus Trust Company's Nektar Therapeutics position peaked at $183K in Q3 2020.
246 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2020.

Based on Petrus Trust Company's 13F filing for Q4 2020, filed 16 Feb 2021.